Press Release: Bulgarian Cystic Fibrosis Patient Joins International Campaign Standing up for the Rights of Patients to Access Essential Medicines

Bulgarian cystic fibrosis patient joins international campaign standing up for the rights of patients to access essential medicines Rositsa Malinova, a 22-year-old resident of Pazardzhik, Bulgaria, is taking on the…

Continue Reading Press Release: Bulgarian Cystic Fibrosis Patient Joins International Campaign Standing up for the Rights of Patients to Access Essential Medicines
Cystic Fibrosis Patients May Now Be Able to Have Hearing Loss Screenings Done Via Tablets
source: pixabay.com

Cystic Fibrosis Patients May Now Be Able to Have Hearing Loss Screenings Done Via Tablets

by Danielle Bradshaw from In The Cloud Copy A recently performed study has demonstrated that it is possible to use tablets to screen patients that have chronic lung conditions -…

Continue Reading Cystic Fibrosis Patients May Now Be Able to Have Hearing Loss Screenings Done Via Tablets
Six Grants From the FDA Will Help Fund Critical Rare Disease Clinical Trials
source: pixabay.com

Six Grants From the FDA Will Help Fund Critical Rare Disease Clinical Trials

According to a story from BioSpace, the US Food and Drug Administration (FDA) recently announced that it has awarded grant funding that will go towards six clinical trials that will…

Continue Reading Six Grants From the FDA Will Help Fund Critical Rare Disease Clinical Trials
The FDA Has Provided 16 Million Dollars to Scientists to Continue Rare Disease Research During the Pandemic
source: pixabay.com

The FDA Has Provided 16 Million Dollars to Scientists to Continue Rare Disease Research During the Pandemic

 The United States FDA has just announced that they will be providing  6 new grants, which are worth 16 million dollars for rare disease research. These grants will last a…

Continue Reading The FDA Has Provided 16 Million Dollars to Scientists to Continue Rare Disease Research During the Pandemic
KALYDECO Now the First FDA-Approved CFTR Modulator for Pediatric Patients with Cystic Fibrosis
1041483 / Pixabay

KALYDECO Now the First FDA-Approved CFTR Modulator for Pediatric Patients with Cystic Fibrosis

  On September 25, biotechnology company Vertex Pharmaceuticals Incorporated ("Vertex") announced FDA-approval of KALYDECO (ivacaftor) for pediatric patients with cystic fibrosis (CF). Specifically, KALYDECO can treat infants between 4-6 months…

Continue Reading KALYDECO Now the First FDA-Approved CFTR Modulator for Pediatric Patients with Cystic Fibrosis